Organogenesis Holdings Inc. (FRA:2PQ)

Market Cap	566.95M
Revenue (ttm)	396.51M
Net Income (ttm)	-7.86M
Shares Out	n/a
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	20.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,705
Average Volume	1,163
Open	4.640
Previous Close	4.620
Day's Range	4.420 - 4.740
52-Week Range	2.300 - 6.000
Beta	n/a
RSI	50.22
Earnings Date	Feb 27, 2026

About Organogenesis Holdings

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic fo...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Gary Gillheeney
• Employees: 869
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2PQ

Financial Performance

Financial numbers in USD